Pirlindole mesylateMAO-A inhibitor CAS# 207572-66-5 |
- GSK256066 2,2,2-trifluoroacetic acid
Catalog No.:BCC1605
CAS No.:1415560-64-3
- Nortadalafil
Catalog No.:BCC1806
CAS No.:171596-36-4
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Oglemilast
Catalog No.:BCC1817
CAS No.:778576-62-8
- AN-2728
Catalog No.:BCC1361
CAS No.:906673-24-3
Quality Control & MSDS
Chemical structure
3D structure
Number of papers citing our products
| Cas No. | 207572-66-5 | SDF | Download SDF |
| PubChem ID | 2829432 | Appearance | Powder |
| Formula | C16H22N2O3S | M.Wt | 322.42 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 50 mM in water with gentle warming | ||
| SMILES | CC1=CC2=C(C=C1)N3CCNC4C3=C2CCC4.CS(=O)(=O)O | ||
| Standard InChIKey | PVUYTBQAVAYLDE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H18N2.CH4O3S/c1-10-5-6-14-12(9-10)11-3-2-4-13-15(11)17(14)8-7-16-13;1-5(2,3)4/h5-6,9,13,16H,2-4,7-8H2,1H3;1H3,(H,2,3,4) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | A highly selective reversible inhibitor of monoamine oxidase type A. |
Pirlindole mesylate Dilution Calculator
Pirlindole mesylate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1015 mL | 15.5077 mL | 31.0154 mL | 62.0309 mL | 77.5386 mL |
| 5 mM | 0.6203 mL | 3.1015 mL | 6.2031 mL | 12.4062 mL | 15.5077 mL |
| 10 mM | 0.3102 mL | 1.5508 mL | 3.1015 mL | 6.2031 mL | 7.7539 mL |
| 50 mM | 0.062 mL | 0.3102 mL | 0.6203 mL | 1.2406 mL | 1.5508 mL |
| 100 mM | 0.031 mL | 0.1551 mL | 0.3102 mL | 0.6203 mL | 0.7754 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (±)-1-(1,2-Diphenylethyl)piperidine maleate
Catalog No.:BCC6619
CAS No.:207461-99-2
- BTCP maleate
Catalog No.:BCC6753
CAS No.:207455-25-2
- L-693,403 maleate
Catalog No.:BCC5657
CAS No.:207455-21-8
- N-MPPP Hydrochloride
Catalog No.:BCC5672
CAS No.:207452-97-9
- Arteannuin N
Catalog No.:BCN4907
CAS No.:207446-92-2
- Arteannuin M
Catalog No.:BCN4906
CAS No.:207446-90-0
- Arteannuin L
Catalog No.:BCN4905
CAS No.:207446-89-7
- MR 16728 hydrochloride
Catalog No.:BCC6684
CAS No.:207403-36-9
- 3-Bromocytisine
Catalog No.:BCC7705
CAS No.:207390-14-5
- Dihydrosinapylalcohol
Catalog No.:BCN6542
CAS No.:20736-25-8
- Saikosaponin A
Catalog No.:BCN1086
CAS No.:20736-09-8
- Saikosaponin C
Catalog No.:BCN1087
CAS No.:20736-08-7
- iso-PPADS tetrasodium salt
Catalog No.:BCC6749
CAS No.:207572-67-6
- SB 203186 hydrochloride
Catalog No.:BCC5673
CAS No.:207572-69-8
- H-Phe(4-NO2)-OH.H2O
Catalog No.:BCC3273
CAS No.:207591-86-4
- TPT-260 Dihydrochloride
Catalog No.:BCC5172
CAS No.:2076-91-7
- HS 014
Catalog No.:BCC5819
CAS No.:207678-81-7
- 5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)
Catalog No.:BCC4583
CAS No.:207679-81-0
- 1,7-Bis(4-hydroxyphenyl)-3-hydroxy-1,3-heptadien-5-one
Catalog No.:BCN6470
CAS No.:207792-17-4
- Propofol
Catalog No.:BCC9130
CAS No.:2078-54-8
- Isobavachalcone
Catalog No.:BCN5415
CAS No.:20784-50-3
- 4'-O-Methylbroussochalcone B
Catalog No.:BCN4908
CAS No.:20784-60-5
- Hemokinin 1 (mouse)
Catalog No.:BCC5774
CAS No.:208041-90-1
- Z-Ser(Bzl)-OH
Catalog No.:BCC2742
CAS No.:20806-43-3
Characterization of the binding site for d-deprenyl in human inflamed synovial membrane.[Pubmed:29221756]
Life Sci. 2018 Feb 1;194:26-33.
AIMS: d-Deprenyl when used as a positron emission tomography tracer visualizes peripheral inflammation. The major aim of the current study was to identify and investigate the properties of the binding target for d-deprenyl in synovial membrane explants from arthritic patients. MAIN METHODS: Thirty patients diagnosed with arthritis or osteoarthritis were enrolled into the study. Homologous and competitive radioligand binding assays utilizing [(3)H]d-deprenyl were performed to investigate the biochemical characteristics of the binding site and assess differences in the binding profile in synovial membranes exhibiting varying levels of inflammation. KEY FINDINGS: The [(3)H]d-deprenyl binding assay confirmed the existence of a single, saturable population of membrane-bound protein binding sites in synovial membrane homogenates. The macroscopically determined level of inflammation correlated with an increase in [(3)H]d-deprenyl binding affinity, without significant alterations in binding site density. Selective monoamine oxidase B inhibitor, selegiline competed for the same site as [(3)H]d-deprenyl, but failed to differentiate the samples with regard to their inflammation grade. A monoamine oxidase A inhibitor, Pirlindole mesylate showed only weak displacement of [(3)H]d-deprenyl binding. No significant alterations in monoamine oxidase B expression was detected, thus it was not confirmed whether it could serve as a marker for ongoing inflammation. SIGNIFICANCE: Our study was the first to show the biochemical characteristics of the [(3)H]d-deprenyl binding site in inflamed human synovium. We confirmed that d-deprenyl could differentiate between patients with varying severity of synovitis in the knee joint by binding to a protein target distinct from monoamine oxidase B.
Pharmacological properties of 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino [3,2,1-j,k]carbazol hydrochloride (pirlindole), a new antidepressant.[Pubmed:7194096]
Arzneimittelforschung. 1981;31(1):75-9.
The hydrochloride salt of 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazol hydrochloride (pirlindole) exerts pharmacological effects typical of antidepressants. This compound antagonizes the depressant effects of reserpine and tetrabenazine and potentiates the central effects of amphetamine and l-dopa. It also enhances the head-twitch effect of 5-hydroxy-tryptophan, the effects of noradrenaline, adrenaline, serotonin, tyramine on blood pressure as well as the hypertensive and tremor activities of tryptamine. Pirlindole inhibits the neuronal uptake of noradrenaline and exerts reversible, short-lasting anti-MAO activity. It does not possess anti-cholinergic activity. Clinical trials have shown pirlindole to be effective as an antidepressive drug.
